angioplasty

Reestenosis de bordes con stents liberadores de everolimus

Arterial Patency in Femoropopliteal Disease with Drug-Eluting Balloons

Follow-up of drug-coated balloon angioplasty in femoropopliteal disease in a real-world population. Using drug-releasing devices has decreased the rate of restenosis in obstructive femoropopliteal lesions compared with conventional balloons or conventional stents (bare-nitinol stent, BNS). Both in the placement of BNS and of drug-eluting stents (DES) there is a mechanical risk of stent fracture or<a href="https://solaci.org/en/2023/02/22/arterial-patency-in-femoropopliteal-disease-with-drug-eluting-balloons/" title="Read more" >...</a>

POKI: una nueva estrategia en bifurcaciones

Intracoronary Brachytherapy for Drug-Eluting Stent Restenosis

3 Year Clinical Outcome Analysis and Failure Predictors in the Use of Intracoronary Brachytherapy for Drug-Eluting Stent Restenosis In-stent restenosis (ISR) has been one of the greatest obstacles standing in the way of long term patency in percutaneous coronary interventions. However, the use of drug eluting stents (DES) and their development has helped reduce ISR<a href="https://solaci.org/en/2023/02/14/intracoronary-brachytherapy-for-drug-eluting-stent-restenosis/" title="Read more" >...</a>

SOLACI Peripheral Registry Hits the 1000-Patient Mark

We are very proud to say that our multicenter, prospective research registry continues to grow by leaps and bounds. We want to congratulate the 36 centers from the 9 participating countries and invite the entire community to join this research initiative that aims to collect data on the reality of lower limb angioplasty in Latin<a href="https://solaci.org/en/2023/02/13/solaci-peripheral-registry-hits-the-1000-patient-mark/" title="Read more" >...</a>

¿Cuál es la mejor antiagregación en la angioplastia primaria a 12 meses?

Monotherapy with P2Y12 in Complex Interventions: Less and Less Risky

&nbsp;Monotherapy in patients with complex angioplasty: meta-analysis of 5 randomized studies.&nbsp; Even though prolonged dual antiplatelet therapy (DAPT) might reduce the risk of important ischemic complications, this reduction will come at the expense of a significant increase of bleeding risk, which makes us reassess the cost benefit ratio of this decision. This is also why<a href="https://solaci.org/en/2023/02/10/monotherapy-with-p2y12-in-complex-interventions-less-and-less-risky/" title="Read more" >...</a>

DISRUPT-PAD III: Seguimiento del tratamiento con IVL en territorio femoropoplíteo

Stent Revascularization in Femoropopliteal Disease: An Analysis of Clustered Randomized Trials

A study compared pooled data of claudication and critical ischemia patients treated with stenting vs. by-pass surgery in femoropopliteal disease. The main objective of revascularization in femoropopliteal disease is to improve the quality of life and functional capacity of claudication patients who did not respond to medical treatment, and to save the affected limb in<a href="https://solaci.org/en/2023/02/07/stent-revascularization-in-femoropopliteal-disease-an-analysis-of-clustered-randomized-trials/" title="Read more" >...</a>

FFR Post Angioplastia

Can Drug Coated Balloon Be a Valid Option for Small Vessels?

One of the challenges of percutaneous coronary interventions (PCI) are &lt;2.5 mm vessels, since complications and restenosis complications rate are higher than with &gt;3.0 mm vessels.&nbsp;&nbsp; Drug Coated Balloons (DCB) can be a useful tool, but their efficacy and safety [vs. plain old balloon angioplasty] remains unclear.&nbsp; PEPCAD China SVD is a prospective and multicenter<a href="https://solaci.org/en/2023/02/06/can-drug-coated-balloon-be-a-valid-option-for-small-vessels/" title="Read more" >...</a>

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

IN.PACT Study | Should We Start Using DCBs More Frequently in Cases of Femoropopliteal Disease?

With the new devices (drug-eluting balloons [DEB], drug-eluting stents [DES], and atherotomes) percutaneous treatment is becoming the first line of approach for femoropopliteal disease, especially when dealing with not very long total occlusions. Randomized studies and registries on the use of drug-coated balloons (DCB) in femoropopliteal disease are currently available, but their evolution beyond 2<a href="https://solaci.org/en/2023/01/30/in-pact-study-should-we-start-using-dcbs-more-frequently-in-cases-of-femoropopliteal-disease/" title="Read more" >...</a>

FRAME-AMI: FFR vs. Angiography of Non-Culprit Vessel in ACS

This study compared fractional flow reserve (FFR) vs. angiography to guide the angioplasty of non-culprit vessels in patients with acute coronary syndrome (ACS) and multivessel disease. Landmark studies such as COMPLETE, COMPARE-ACUTE and DANAMI-3-PRIMULTI have demonstrated the prognostic value of revascularization (after treatment of the artery responsible for the ACS) of non-culprit arteries with respect<a href="https://solaci.org/en/2023/01/25/frame-ami-ffr-vs-angiography-of-non-culprit-vessel-in-acs/" title="Read more" >...</a>

La coronariografía precoz reduce la mortalidad en SCA sin supradesnivel del ST de alto riesgo

Long-Term Evolution of Hybrid Coronary Revascularization

Currently, myocardial revascularization surgery (MRS) and percutaneous coronary intervention (PCI) are the available strategies for multivessel coronary artery disease. However, an alternative strategy has long been developed, called hybrid coronary revascularization (HCR), where the anterior descending artery is bypassed with a graft from the mammary artery and the rest of the lesions are treated by<a href="https://solaci.org/en/2023/01/23/long-term-evolution-of-hybrid-coronary-revascularization/" title="Read more" >...</a>

The Most Important Articles of 2022 in Peripheral Vascular Disease

Discover the most important scientific articles of 2022 in peripheral vascular disease in our website. EMINENT Trial | Stent Eluvia vs BMS in Femoropopliteal Territory Endovascular therapy in femoropopliteal territory has become the standard, mainly with self-expanding stents, aimed at preventing early vascular recoil and late constrictive remodeling.&nbsp; Thromboendarterectomy vs. Endovascular Therapy in Common Femoropopliteal<a href="https://solaci.org/en/2023/01/19/the-most-important-articles-of-2022-in-peripheral-vascular-disease/" title="Read more" >...</a>

Top